Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · CVS Health (CVS)

CVS Health names JPMorgan executive Teresa Heitsenrether to board; Larry Robbins resigns

Neutral Impact 2 of 5 leadership Written later

CVS Health appointed Teresa Heitsenrether, Executive Vice President and Chief Data & Analytics Officer at JPMorgan Chase, to its Board of Directors, effective November 18, 2026. Larry Robbins resigned from the Board effective August 13, 2026, and the company said his resignation was not due to any disagreement with the company. The filing reports no financial results, so the change is a board composition update rather than a change to company performance.

Key points

  • Teresa Heitsenrether joins the Board effective November 18, 2026, and was determined to be independent under NYSE rules.
  • Larry Robbins resigned from the Board effective August 13, 2026, after serving since 2024.
  • Heitsenrether's director compensation will match other non-employee directors, prorated for her start date.
  • CEO David Joyner said Heitsenrether brings experience in data, analytics and technology.

The filing

CompanyCVS Health (CVS)
Form8-K, current report
Filed with the SECAug 17, 2026, 4:19 PM ET
Accession number0001193125-26-354096

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:21 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 17, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.